RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1189 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN), maintaining a price target of $1189.
April 09, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Regeneron Pharmaceuticals with a price target of $1189.
The reiteration of an Outperform rating by a prominent analyst like Brian Abrahams, along with a high price target, suggests a strong bullish outlook for Regeneron Pharmaceuticals. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90